Related Experiment Video
Updated: Oct 26, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report
Yi-Feng Wu1, Wan-Jun Yu2, Yu-Hua Jiang3
1Department of Hepatobiliary and Pancreas Surgery, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China.
Background:
Since the initial recognition of coronavirus disease 2019 (COVID-19) in Wuhan, this infectious disease has spread to most areas of the world. The pathogenesis of COVID-19 is yet unclear. Hepatitis B virus (HBV) reactivation occurring in COVID-19 patients has not yet been reported.
Case Summary:
A 45-year-old hepatitis B man with long-term use of adefovir dipivoxil and entecavir for antiviral therapy had HBV reactivation after being treated with methylprednisolone for COVID-19 for 6 d.
Conclusion:
COVID-19 or treatment associated immunosuppression may trigger HBV reactivation.

